Pediatrics & Therapeutics
Open Access
ISSN: 2161-0665
+44 1478 350008
ISSN: 2161-0665
+44 1478 350008
G. A. Khakimov, B. B. Negmajanov and F. I. Zokirov
Tashkent Pediatric Medical Institute, Uzbekistan
Posters & Accepted Abstracts: Pediatr Therapeut
Breast cancer (BC) is the most common cause of cancer – related mortality in women. Th e main cause of mortality in this group is generalization of BC with development of polyorganic insuffi ciency in the background of chronic pain syndrome. In this connection the choice of rational methods of palliative therapy remains actual, especially in cases with multiple aff ection nidi.
Objective of the study was to evaluate the volume of palliative chemoradiation therapy implamantation to increase the survival rate of patients.
To research were included 23 women with disseminated breast cancer (DBC) at the age of 34-60 years and they were divided into 2 groups: Th e 1st group consisted of 13 women with distant metastases in liver, bones of skeleton and skin. Th e 2nd group consisted of 10 women with metastases in supraclavicular lymph nodes of aff ected site, in liver and bones of skeleton. Patients of fi rst group in the background of palliative polychemotherapy (PPCT) (4-6 cycles) – taxanes with anthracyclines, received shortfocal therapy in the region of intradermal metastases. Patients of second group received similar PPCT with palliative radiation therapy in supraclavicular region – 40-44 Gy. Patients of both group under control of blood Calcium levels received bisphosphonates.
In patients with DBC in both of group average time for disease progression as development of polyorganic insuffi ciency with sharp limitation of specialized therapy arsenal was 8.7 months. In addition to that local disease control – without signs of lymphostasis and limitations in volume of movement in upper extremity of aff ected site without impairment of patient’s life quality was marked.
Implementation of palliative chemoradiation and X-ray therapy in patients with DBC allows to increase average time of disease progression and life quality of fatally diseased patients with DBC.